Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Risperidone vs. Bupropion ER Augmentation of SSRIs in Treatment-Resistant Depression

This study has been completed.
Janssen Pharmaceutica
Information provided by (Responsible Party):
Richard C. Shelton, Vanderbilt University Identifier:
First received: September 13, 2005
Last updated: June 1, 2015
Last verified: June 2015
The purpose of this study is to evaluate the comparative effectiveness of Risperdal (risperidone) or bupropion ER (extended release) combined with a SSRI medication and to test the relative safety of the combinations.

Condition Intervention Phase
Unipolar Depression
Drug: Rispridone (drug) and Bupropion ER (drug)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Official Title: Risperidone vs. Bupropion ER Augmentation of SSRIs in Treatment-Resistant Depression

Resource links provided by NLM:

Further study details as provided by Vanderbilt University:

Primary Outcome Measures:
  • MADRS (Montgomery Asberg's Depression Rating Scale)

Secondary Outcome Measures:
  • HAM-D(Hamilton Rating Scale for Depression ) 17-item
  • BDI (Beck Depression Inventory)
  • HAM-A (Hamilton Rating Scale for Anxiety)
  • Clinical Global Impression Scale and Severity and Improvement.

Estimated Enrollment: 30
Study Start Date: July 2004
Study Completion Date: April 2005
Detailed Description:

Major depression is a severe disorder with serious consequences. Effective treatments are available; however, in clinical trials 30-40% of patients do not experience even a 50% reduction in depression severity scores, while 50-70% fail to achieve a full therapeutic response. Futhermore, impairment from the disorder continues essentially unabated in patients who are treated but do not fully remit. If anything, the situation is at least as bad or not worse in clinical practice. Clearly, alternatives are needed to manage this common clinical condition.

The addition of bupropion ER (extended release) to an SSRI has empirical support, and has become the most common augmentation strategy in the US. A comparative trial of the combination of risperidone or bupropion ER added to an SSRI in treatment resistant deperssion could help support risperidone for this condition; such a trial seems warranted at this time.

Patients who are currently on a SSRI at an adequate dosage for at least 3 weeks with no response, will be randomly assigned (open-label) to either risperidone or bupropion ER augmentation for a period of 6 weeks. Patients will be followed weekly at the beginning and bi-weekly towards the end of the trial to compare the response of each group.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female 18 years or older
  • DSM-IV diagnosis of major depressive disorder of at least moderate severity, but without psychotic features
  • Ham-D 17 score of 18 or above
  • Have a documentable history of 2 prior adequate trials of antidepressants including an SSRI without sufficient response. A clinically adequate trial is defined as having taken a minimum effective dose of an antidepressant for at least 3 weeks without a significant change in depressive symptoms.
  • Must be currently on an serotonin uptake inhibitor (to include venlafaxine or duloxetine) at an adequate dose for at least 3 weeks.
  • Ability and willingness to provide consent for participation in the study.

Exclusion Criteria:

  • Any medical condition that would preclude treatment with an SSRI, risperidone, or bupropion ER
  • Any clinically significant unstable medical condition
  • Diagnosis of bipolar disorder or a primary diagnosis of any psychotic disorder
  • Current psychotic symptoms (hallucination or delusions)
  • Alcohol or drug abuse or dependence in the last 3 months (excluding nicotine and caffeine dependence/abuse) or abuse within the last month
  • Documented non-response to the combination of a novel antipsychotic or bupropion ER and a SSRI
  • Concomitant use of any psychotropic other than an SSRI or zolpidem (PRN for sleep)
  • Score of 4 on the suicide item of the Ham-D scale and determination by the investigator of significant suicide risk
  • Known sensitivity to risperidone or bupropion ER
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00179244

United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37211
Sponsors and Collaborators
Vanderbilt University
Janssen Pharmaceutica
Principal Investigator: Richard C Shelton, MD Vanderbilt University Medical Center
  More Information

Responsible Party: Richard C. Shelton, Director of Mood Disorder Clinic, Vanderbilt University Identifier: NCT00179244     History of Changes
Other Study ID Numbers: RIS vs. BUP Augmentation Depr.
Study First Received: September 13, 2005
Last Updated: June 1, 2015

Keywords provided by Vanderbilt University:
Treatment Resistant Depression

Additional relevant MeSH terms:
Depressive Disorder
Depressive Disorder, Treatment-Resistant
Behavioral Symptoms
Mood Disorders
Mental Disorders
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Serotonin Antagonists
Serotonin Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Dopamine Antagonists processed this record on April 28, 2017